Transient partial response to sorafenib treatment in an adolescent patient with MEN2B Syndrome and end-stage medullary thyroid carcinoma

  • Aller S
  • Popescu A
  • Rao S
 et al. 
  • 16


    Mendeley users who have this article in their library.
  • 4


    Citations of this article.


Metastatic medullary thyroid carcinoma (MTC) is an aggressive malignancy with an extremely poor prognosis. Currently no effective conventional systemic therapies exist to treat pediatric MTC. We describe an adolescent female with newly diagnosed MEN2B syndrome who presented with advanced stage metastatic MTC and demonstrated a partial transient response to sorafenib monotherapy. This clinical result supports further research into the use of sorafenib in the treatment of pediatric MTC. © 2011 Wiley Periodicals, Inc.

Author-supplied keywords

  • MEN2B syndrome
  • Metastatic medullary thyroid carcinoma
  • Sorafenib

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Steven Aller

  • Andrada Popescu

  • Sudha Rao

  • Elaine Morgan

  • Yasmin Gosiengfiao

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free